Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 07 2020
Historique:
received: 18 11 2019
revised: 30 03 2020
accepted: 31 03 2020
pubmed: 15 4 2020
medline: 16 2 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Postoperative radiation therapy (poRT) of intracranial/skull base chondrosarcomas (CHSs) is standard treatment. However, consensus is lacking for poRT in extracranial CHS (eCHS) owing to their easier resectability and intrinsic radioresistance. We assessed the practice and efficacy of poRT in eCHS. This multicentric retrospective study of the French Sarcoma Group/Rare Cancer Network included patients with eCHS who were operated on between 1985 and 2015. Inverse propensity score weighting (IPTW) was used to minimize poRT allocation biases. Of 182 patients, 60.4% had bone and 39.6% had soft-tissue eCHS. eCHS were of conventional (31.9%), myxoid (28.6%; 41 extraskeletal, 11 skeletal), mesenchymal (9.9%), or other subtypes. En-bloc surgery with complete resection was performed in 52.6% and poRT in 36.8% of patients (median dose, 54 Gy). Irradiated patients had unfavorable initial characteristics, with higher grade and incomplete resection. Median follow-up time was 61 months. Five-year incidence of local relapse was 10% with poRT versus 21.6% without (P = .050). Using the IPTW method, poRT reduced the local relapse risk (hazard ratio, 0.27; 95% confidence interval, 0.14-0.52; P < .001). Five-year disease-free survival (DFS) was 71.8% with poRT and 64.2% without (P = .680). Using the IPTW method, poRT improved DFS (hazard ratio, 0.51; 95% confidence interval, 0.30-0.85; P = .010). The benefit of poRT on local relapse and DFS was confirmed after exclusion of the extraskeletal subtype. There was no difference in overall survival. Prognostic factors of poorer DFS in multivariate analysis were deeper location, higher grade, incomplete resection, and no poRT. poRT should be offered in patients with eCHS and high-grade or incomplete resection, regardless of the histologic subtype.

Identifiants

pubmed: 32289473
pii: S0360-3016(20)30985-8
doi: 10.1016/j.ijrobp.2020.03.041
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-735

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Mario Terlizzi (M)

Department of Radiation Oncology, Institut Bergonie, Bordeaux, France.

Cécile Le Pechoux (C)

Institut Gustave Roussy, Villejuif, France.

Sébastien Salas (S)

Assistance Publique Hôpitaux de Marseille, Timone Hospital, Marseille, France.

Etienne Rapeaud (E)

Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France.

Delphine Lerouge (D)

Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France.

Marie P Sunyach (MP)

Centre Léon Berard, Lyon, France.

Guillaume Vogin (G)

Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France.

Claudio V Sole (CV)

Clinica Instituto de Radiomedicina (IRAM) and Facultad de Medicina, Universidad Diego Portales, Santiago, Chile; Facultad de Medicina, Universidad Diego Portales, Santiago, Chile.

Thomas Zilli (T)

Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.

Myroslav Lutsyk (M)

Rambam HCC, Haïfa, Israel.

Ange Mampuya (A)

Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Felipe A Calvo (FA)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Justine Attal (J)

IUCT-Oncopole, Toulouse, France.

Vardouhie Karahissarlian (V)

Centre Léon Berard, Lyon, France.

Berardino De Bari (B)

Centre Hospitalier Régional Universitaire "Jean Minjoz," Université de Bourgogne-Franche Comté, Besançon, France.

Mahmut Ozsahin (M)

Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Florian Baumard (F)

Department of Biostatistics, Institut de Cancérologie de Lorraine, Université de Lorraine, Vandœuvre-lès-Nancy, France.

Marco Krengli (M)

Department of Radiation Oncology, University Hospital, Novara, Italy.

Anne Gomez-Brouchet (A)

Department of Pathology, University Hospital of Toulouse, Toulouse, France.

Paul Sargos (P)

Department of Radiation Oncology, Institut Bergonie, Bordeaux, France.

Goulven Rochcongar (G)

Department of Orthopedics, University Hospital of Caen, Caen, France.

Céline Bazille (C)

Department of Pathology, University Hospital of Caen, Caen, France.

Vincent Roth (V)

Easy-CRF SAS, Mathieu, France.

Julia Salleron (J)

Department of Biostatistics, Institut de Cancérologie de Lorraine, Université de Lorraine, Vandœuvre-lès-Nancy, France.

Juliette Thariat (J)

Department of Radiation Oncology, Centre Baclesse/ARCHADE-Normandie Université, Caen, France; Laboratoire de Physique Corpusculaire, Caen, France; Unicaen-Normandie Université, Caen, France. Electronic address: jthariat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH